Sorted By Test Name - Mayo Medical Laboratories

FPSAU
91817
PACP
8019
Clinical References: 1. Oesterling JE, Jacobsen SJ, Chute CG, et al: Serum Prostate-Specific
Antigen in a Community-Based Population of Healthy Men. JAMA 1993 Aug 18; 270:860-864 2.
Catalona WJ, Smith DS, Wolfert RL, et al: Evaluation of percentage of free serum prostate-specific
antigen to improve specificity of prostate cancer screening. JAMA 1995:274(15);214-1220 3. Jacobsen
SJ, Bergstralh EJ, Guess HA, et al: Predictive properties of serum prostate-specific antigen testing in a
community-based setting. Arch Intern Med 1996;156:2462-2468 4. Oesterling JE, Jacobsen SJ, Klee GG,
et al: Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference
ranges for their concentrations and ratios. J Urol 1995;154:1090-1095 5. Dworschack RT, Thiel RP,
Picolli SP. Clinical Evaluation of the free/total PSA ratio generated with the Elecsys Total and Free PSA
assays on the Elecsys 1010 and 2010 systems. Clin Chem 2001 Jun; 47 (6 Suppl S):A149. (Abstract)
Prostate-Specific Antigen, Ultrasensitive
Reference Values:
0.0 00 - 4.000 ng/mL
Roche ECLIA methodology
According to the American Urological Association, Serum PSA should decrease and remain at
undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial
PSA value 0.200 ng/mL or greater followed by a subsequent confirmatory PSA value 0.200 ng/mL or
greater.
Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be
interpreted as absolute evidence of the presence or absence of malignant disease.
Test Performed by: LabCorp Burlington
1447 York Court
Burlington, NC 27215
Prostatic Acid Phosphatase (PAP), Serum
Clinical Information: Prostatic acid phosphatase (PAP), a glycoprotein synthesized by the prostate
gland, is a member of a diverse group of isoenzymes, the acid phosphatases, which are capable of
hydrolyzing phosphate esters in acidic medium. They are classified on the basis of their electrophoretic
mobilities. PAP was a major tumor marker for prostate cancer for more than 50 years.(1) However, PAP
is no longer used to screen for or stage prostate cancer. In most instances, serum prostate specific antigen
(PSA) is used instead. PAP usefulness is now limited to niche applications. Pre-treatment PAP
measurement may add unique, clinically useful prognostic information for predicting recurrence in men
who are undergoing radical prostatectomy for clinically localized prostate cancer. PAP also may be useful
for following the progression of disease response to therapy in men treated by androgen ablation.
However, for both of these applications, PSA provides more information and also should be utilized.
Useful For: Predicting recurrence after radical prostatectomy for clinically localized prostate cancer
and following response to androgen ablation therapy, when used in conjunction with prostate-specific
antigen
Interpretation: Prostatic acid phosphatase (PAP) levels above the reference range may indicate
prostate cancer, but can be due to many other factors, see Cautions. A rise in PAP levels in patients with
known prostate cancer can indicate tumor progression or recurrence. However, there is considerable
intra-subject biological variability, limiting the usefulness of this test.
Reference Values:
< or =2.1 ng/mL
Clinical References: 1. Moul JW, Connelly RR, Perahia B, McLeod DG: The contemporary value
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 1489